Aaron B. Waxman, MD, PhD Associate Professor Department of Medicine Harvard Medical School Director, Pulmonary Vascular Disease Program Pulmonary and Critical Care Medicine Cardiovascular Medicine Brigham and Women’s Hospital Boston, MA
Roham T. Zamanian, MD, FCCP Assistant Professor of Medicine Director, Adult Pulmonary Hypertension Clinical Service Vera Moulton Wall Center for Pulmonary Vascular Disease Division of Pulmonary & Critical Care Medicine Stanford University Medical Center Stanford, CA
AMA PRA Category 1 Credits TM. Medium
NOTE: This article was originally published as a supplement to the American Journal of Cardiology (Volume 111, Issue 5, Supplement, Pages 1A-16A, 4 March 2013). If you received credit for reviewing the printed supplement, you are not eligible to receive credit for this online release.
Please carefully read the instructions below (in red) to learn how to return to CMEcorner.com to take the post-test and receive CME credit for this activity.
Pulmonary arterial hypertension (PAH), which is a subset of pulmonary hypertension, is a group of diseases distinguished by vascular remodeling of the small pulmonary arteries with associated elevated pulmonary arterial pressure and right ventricular failure. This progressive and sometimes fatal disease occurs as an idiopathic disease or as a component of other disease states. Estimates of the incidence of PAH vary from 5 to 52 cases per million population. This paper (originally published in a supplement to the American Journal of Cardiology) provides an overview of PAH, the scientific rationale for treatment with prostacyclin therapy, and the benefits and risks of prostacyclin therapy, both as monotherapy and in combination with other medications approved for the treatment of PAH. Program Developer/Facilitator
Temple University School of Medicine and MCM Education
This educational activity is designed to meet the needs of cardiologists, pulmonologists, critical care practitioners, and other clinicians involved in the care of patients with PAH.
Upon completion of this educational activity, the participant should be able to:
Review the pathophysiology of PAH and the scientific rationale for treatment with prostacyclin therapy.
Compare the risk-benefit profiles of available prostacyclin therapies and formulations for the treatment of PAH.
Develop safe and effective combination PAH treatment approaches that target the prostacyclin pathway as well as other mechanisms that lead to PAH.
Review recent data on emerging prostacyclin therapies for treatment of PAH.
It is the policy of Temple University School of Medicine; The Albert J. Finestone, MD Office for Continuing Medical Education to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored or jointly sponsored educational programs. All faculty, program planning committee members, and Temple University School of Medicine Continuing Medical Education staff participating in programs sponsored or jointly sponsored by Temple University School of Medicine are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of the presentation(s).
Planning Committee Disclosure Statement: Planning committee members have no financial relationships to disclose.
Faculty Disclosure Statements:
Dr. Waxman discloses that he has received grant/research support from United Therapeutics Corp.; Gilead; Pfizer Inc.; Medtronic, Inc.; Actelion Pharmaceuticals US, Inc.; Bayer AG; Aries Pharmaceuticals, Inc.; and GeNO LLC.
Dr. Zamanian discloses that he has received grant/research support from United Therapeutics Corp. and Actelion Pharmaceuticals US, Inc. He has served as a consultant for United Therapeutics Corp.; Actelion Pharmaceuticals US, Inc.; Gilead; Bayer AG; and Ikaria, Inc.
Accreditation Statement: Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for physicians.
Certification Statement: Temple University School of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There is no fee to participate and receive credit.
Credit Provider Contact Information:
Temple University School of Medicine
The Albert J. Finestone, MD Office for CME
3440 North Broad Street
Philadelphia, PA 19140
Commercial Support Statements
This activity is supported by an independent educational grant from United Therapeutics Corporation.
Minimum System Requirements
• Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color
Please turn off all pop-up blockers to ensure access to the educational activity.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com user or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
You will be directed to an American Journal of Cardiology table of contents, which lists two articles. Click on the first article.
After viewing the article, return to the AJC table of contents and click on the second article to take the post-test and claim your CME credit. Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.
The activity will take approximately 60 minutes to complete.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional and, therefore, cannot be considered as giving legal, medical, or other professional advice in specific cases. Temple University, the author(s), and the publisher specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader's misunderstanding of the content.